Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 6

Use of Trastuzumab Deruxtecan in Ovarian Cancer

October 14, 2024

Angeles Alvarez Secord, MD, MHSc , Dana M. Chase, MD, FACOG, Bhavana Pothuri, MD, Premal H. Thaker, MD, MS, Thomas C. Krivak, MD

Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, its potential impact on treating advanced ovarian cancer given HER2 data, and how T-DXd may fit into the current treatment algorithm for ovarian cancer.

EP. 1: Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP. 2: Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer

EP. 3: Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

EP. 4: Emerging Combinations in Maintenance Therapy for Ovarian Cancer

EP. 5: Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation

Now Viewing

EP. 6: Use of Trastuzumab Deruxtecan in Ovarian Cancer

EP. 7: Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

EP. 8: Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches

EP. 9: Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

EP. 10: Biomarker Testing in Advanced Endometrial Cancer: Approach, Key Markers, and Impact on Treatment Decisions

EP. 11: Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights

EP. 12: Durvalumab in Endometrial Cancer: DUO-E Trial Updates

EP. 13: Innovative Combination Strategies for Endometrial Cancer: Updates from LEAP and KEYNOTE-B21 Trials

EP. 14: T-DXd in Advanced Endometrial Cancer

EP. 15: Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Video content above is prompted by the following:

Briefly comment on the recent tumor agnostic approval for trastuzumab deruxtecan (T-DXd) based on the findings from DESTINY-PanTumor02.
Based on available HER2 data in ovarian cancer, what impact will this have on the treatment of advanced ovarian cancer?
Where do you see T-DXd fitting in your treatment algorithm for ovarian cancer?